Spondyloarthritis

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.

Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.

Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.

Full 52-week results of the SPIRT-H2H trial were presented during the late breaking session at ACR 2019.

Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Philip Mease, MD, Director of Rheumatology Research at Swedish Rheumatology Research Group, reflects upon new data and discusses where he sees guselkumab fitting into a PsA patient's current treatment plan.

Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.

Biologics that target the immune system give doctors an opportunity to treat diseases like psoriasis and atopic dermatitis.

The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.

The new approval represents the third time the FDA approved the injection treatments for adults.

A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.

The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.

A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.

A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.

A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.

Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

Risankizumab (Skyrizi) is now approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

The COAST-X trial evaluated the safety and efficacy of ixekizumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA).

Certolizumab pegol (Cimzia) is the first FDA-approved treatment for the condition.

The first liquid formulation of the common gout therapy is anticipated to improve instances of dosing adjustment for patients.

The immunosuppressive drug was more effective and resulted in fewer adverse events in patients with psoriasis but without psoriatic arthritis.